Full-Time
Document Control Specialist
Posted on 9/16/2025
Sotera Health
1,001-5,000 employees
Outsourced sterilization and lab testing provider.
No salary listed
Salt Lake City, UT, USA
In Person
 Administrative & Executive Assistance (1) |
|---|
- High school diploma and 1–2 years of related experience
- Strong written, verbal, and interpersonal communication skills
- Proficiency in Microsoft Office
- Oversee the global document control process, ensuring timely revision, approval, and archival of controlled documents
- Review and edit documents for grammar, formatting, and compliance with templates
- Coordinate translation of documents into multiple languages, as needed
- Process and distribute customer testing instructions, ensuring timely approval
- Provide document control support in accordance with company procedures and policies
- Associate degree or higher with at least 1 year of relevant experience
- Experience using MasterControl or similar document control systems
Sotera Health provides sterilization and lab testing services to ensure the safety of medical devices, pharmaceuticals, and food products. The company operates through three divisions: Sterigenics, which uses methods like Gamma and X-ray to eliminate contaminants; Nordion, which supplies the Cobalt-60 isotopes needed for irradiation; and Nelson Labs, which performs over 800 microbiological and analytical tests. Unlike many competitors, it offers a fully integrated supply chain by producing its own sterilization sources while maintaining a global network of 63 facilities and labs. Its goal is to protect global health by providing the mission-critical services required to bring safe healthcare products to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Broadview Heights, Ohio
Founded
2017
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $280M, beating estimates with 10% growth and 48.1% EBITDA margin.
- Sessa Capital bought $175.8M stake in Q4 2025, signaling investor confidence.
- CFO guides 5-6.5% organic growth for 2026, targeting $500-600M free cash flow.
What critics are saying
- EPA restricts EtO facilities at Sterigenics, slashing 8% volume growth in 6-12 months.
- Nordion's Cobalt-60 supply fails from aging reactors, crippling gamma operations in 12-24 months.
- Q1 2026 free cash flow drops to negative $16.73M, breaching debt covenants in 6-12 months.
What makes Sotera Health unique
- Sotera Health integrates Sterigenics, Nordion, and Nelson Labs for end-to-end sterilization and testing.
- Nordion supplies Cobalt-60 isotopes essential for Sterigenics' gamma sterilization worldwide.
- Nelson Labs performs over 900 microbiological tests across 15 global labs for validation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Education Assistance
Employee Assistance Program (EAP)
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Detailed price information for Capital One Financial Corp (COF-N) from The Globe and Mail including charting and trades.
Sessa Capital has acquired an additional 10,630,381 shares of Sotera Health for approximately $175.80 million on 17 February 2026, bringing its quarter-end position value to $206.47 million. The transaction signals strong confidence in the healthcare services company. Sotera Health shares traded at $13.99 on Monday, representing an 18% gain over the past year, slightly outperforming the S&P 500's 15% increase. The company has generated revenue of approximately $1.16 billion and adjusted EBITDA near $600 million. Despite facing litigation and regulatory risks, Sotera Health's sustained growth potential continues attracting long-term investor interest. The substantial investment by Sessa Capital reinforces the company's position within the asset manager's portfolio.
Sessa Capital purchased 10.63 million shares of Sotera Health in the fourth quarter for an estimated $175.80 million, according to a Securities and Exchange Commission filing dated 17 February. The stake now represents nearly 7% of Sessa Capital's reportable assets under management. Sotera Health provides sterilisation services and laboratory testing for medical device and pharmaceutical industries. The company generated $1.2 billion in revenue and $77.9 million in net income over the trailing twelve months. Despite 20 years of steady growth and adjusted EBITDA approaching $600 million, the stock has declined as investors focus on litigation risks, high leverage and regulatory concerns. The shares currently trade at $13.99, up 18% over the past year, with a market capitalisation of $4.0 billion.
Sotera Health's CFO Jon Lyons reaffirmed constant-currency organic growth guidance of 5% to 6.5% for 2026 at the KeyBanc Healthcare Forum. Sterigenics is expected to deliver mid- to high-single-digit growth, whilst Nordion and Nelson Labs will see lower-single-digit growth. The company closed 2025 with 5.2% organic revenue growth, maintaining over 50% EBITDA margins with a 118-basis-point improvement. Weaker Nelson Labs results were offset by stronger Sterigenics volumes of approximately 8%. Management prioritises free cash flow and capital discipline, targeting $500 million to $600 million over three years. Capital expenditure is expected to drop significantly in 2027 as projects complete. Net leverage has improved towards the 2x–3x target, providing flexibility for debt reduction, acquisitions or share buybacks.
Ananym Capital Management sold 217,684 shares of Sotera Health for an estimated $3.60 million in February 2026, according to an SEC filing. Despite the sale, Sotera Health remains a significant holding at 8.65% of Ananym's assets under management. Sotera Health shares were trading at $17.09 as of 17 February 2026, up nearly 30% over the past year and outperforming the S&P 500 by 14.86 percentage points. The company provides sterilisation services and laboratory testing for medical device, pharmaceutical and food industries. Sotera recently reported its 20th consecutive year of revenue growth, with 2025 revenues rising nearly 6% to $1.16 billion. Management has guided for another 5% to 6.5% revenue increase in 2026, with adjusted EBITDA growth of 5.5% to 7%.